See Full Report below….
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 153% in verifiable potential gains for our
Members in the last 3 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our members gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49%
for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to
see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and
verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest
of the small-cap newsletters as the best in business. We know with a large following comes a large
responsibility as we have everyone from institutional investors to the beginner following our profiled
securities in our newsletters. This is something we take very seriously always seeking small cap growth
companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time.
We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report:
PALO ALTO, Calif., April 4, 2016 /PRNewswire/ — Eiger BioPharmaceuticals, Inc, (NASDAQ: EIGR) announced today that its Board of Directors has appointed Charles J. “Chuck” Bramlage as a member of the Board.
Mr. Bramlage is a pharmaceutical industry veteran with extensive experience in marketing, sales, and corporate operations spanning large pharma to start up pharma. He is currently the Chief Executive Officer of Pearl Therapeutics, Inc., a development stage start-up company focused on treatments for respiratory diseases that was acquired by AstraZeneca. He previously served as President of Pharmaceutical Products at Covidien plc and President of European Operations at Valeant Pharmaceuticals International, Inc. Earlier in his career, Mr. Bramlage held senior level U.S and International commercial operating positions at GlaxoSmithKline plc and Merck & Company, Inc. Mr. Bramlage and his teams have launched over 40 prescription brands across 14 therapeutic areas.
“We enthusiastically welcome Chuck to our Board of Directors and look forward to benefiting from his background and experience as we begin to direct product development toward maximizing market opportunities for each pipeline program,” said Tom Dietz, Ph.D., Eiger’s Chairman of the Board.
David Cory, President and Chief Executive Officer of Eiger, stated, “Chuck brings a wealth of experience in global commercial strategy and operations. He will provide valuable insight as we begin to consider commercial opportunities and market development for each of our multiple, diverse clinical stage programs.”
About Eiger
Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.
Investors: Jim Shaffer, Eiger BioPharmaceuticals, Inc., 919-345-4256,
SOURCE Eiger BioPharmaceuticals, Inc. & Street Insider
Broad Street Alerts has not been compensated for the mention of _NASDAQ; EIGR__ and we do not hold any positions.